The Gog Foundation, Inc

The Gog Foundation, Inc company information, Employees & Contact Information

The GOG Foundation, Inc. (GOG Foundation) is a nonprofit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva. Our institutions and investigators are essential contributors to advancements in treatment regimens, surgical procedures, quality of life analyses, and prevention knowledge. The results of GOG Foundation clinical trials have influenced the standard of care for numerous malignant gynecologic neoplasms.

Company Details

Employees
37
Founded
-
Address
Four Penn Center, 1600 Jfk Blvd
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Keywords
Philadelphia.
HQ
Philadelphia, PA
Looking for a particular The Gog Foundation, Inc employee's phone or email?

The Gog Foundation, Inc Questions

News

Sarasota Memorial Joins Multi-Center Trial of New Drug Targeting Resistant, Late-Stage Ovarian Cancer - Florida Hospital News and Healthcare Report

Sarasota Memorial Joins Multi-Center Trial of New Drug Targeting Resistant, Late-Stage Ovarian Cancer Florida Hospital News and Healthcare Report

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer Business Wire

GOG in 3-D! - Film Forum

GOG in 3-D! Film Forum

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study | Journal of Clinical Oncology - ASCO Publications

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study | Journal of Clinical Oncology ASCO Publications

The GOG Foundation, Inc., the Society of Gynecologic Oncology, and the Foundation for Women’s Cancer announce synergistic partnership to advance the missions of all three organizations - EurekAlert!

The GOG Foundation, Inc., the Society of Gynecologic Oncology, and the Foundation for Women’s Cancer announce synergistic partnership to advance the missions of all three organizations EurekAlert!

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer - The New England Journal of Medicine

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer The New England Journal of Medicine

New stem classroom resources - Royal Society

New stem classroom resources Royal Society

The GOG Foundation, Inc. (GOG-F) and GOG Partners enrolls first patient in for GOG 3068 (HOTT) - EurekAlert!

The GOG Foundation, Inc. (GOG-F) and GOG Partners enrolls first patient in for GOG 3068 (HOTT) EurekAlert!

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer - The New England Journal of Medicine

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer The New England Journal of Medicine

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial | Journal of Clinical Oncology - ASCO Publications

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial | Journal of Clinical Oncology ASCO Publications

Survival with Cemiplimab in Recurrent Cervical Cancer - The New England Journal of Medicine

Survival with Cemiplimab in Recurrent Cervical Cancer The New England Journal of Medicine

ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer - EurekAlert!

ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer EurekAlert!

Reply to P.-H. Luo et al - ASCO Publications

Reply to P.-H. Luo et al ASCO Publications

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer - The New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer The New England Journal of Medicine

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study - ASCO Publications

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study ASCO Publications

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer - The New England Journal of Medicine

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer The New England Journal of Medicine

Reply to C. Marchetti et al | Journal of Clinical Oncology - ASCO Publications

Reply to C. Marchetti et al | Journal of Clinical Oncology ASCO Publications

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer - The New England Journal of Medicine

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer The New England Journal of Medicine

Improved Survival with Bevacizumab in Advanced Cervical Cancer - The New England Journal of Medicine

Improved Survival with Bevacizumab in Advanced Cervical Cancer The New England Journal of Medicine

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer - The New England Journal of Medicine

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer The New England Journal of Medicine

Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study - ASCO Publications

Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study ASCO Publications

Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review - Frontiers

Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review Frontiers

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer - The New England Journal of Medicine

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer The New England Journal of Medicine

Full article: Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online

Full article: Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer Taylor & Francis Online

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer Taylor & Francis Online

RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer - EurekAlert!

RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer EurekAlert!

Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial - ScienceDirect.com

Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial ScienceDirect.com

Full article: RaPiDS (GOG-3028): Randomized Phase II Study of Balstilimab Alone or in Combination with Zalifrelimab in Cervical Cancer - Taylor & Francis Online

Full article: RaPiDS (GOG-3028): Randomized Phase II Study of Balstilimab Alone or in Combination with Zalifrelimab in Cervical Cancer Taylor & Francis Online

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer - The New England Journal of Medicine

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer The New England Journal of Medicine

Dynamics and selection of many-strain pathogens - PNAS

Dynamics and selection of many-strain pathogens PNAS

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer - The New England Journal of Medicine

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer The New England Journal of Medicine

Promising first results of new maintenance therapy for advanced or recurrent endometrial cancer - UZ Leuven

Promising first results of new maintenance therapy for advanced or recurrent endometrial cancer UZ Leuven

Role of complete lymphadenectomy in endometrioid uterine cancer - The Lancet

Role of complete lymphadenectomy in endometrioid uterine cancer The Lancet

SMH one of 30 sites for late-stage ovarian cancer drug trial - Sarasota Herald-Tribune

SMH one of 30 sites for late-stage ovarian cancer drug trial Sarasota Herald-Tribune

Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial - RSNA Journals

Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial RSNA Journals

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer - The New England Journal of Medicine

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer The New England Journal of Medicine

A Phase 3 Trial of Bevacizumab in Ovarian Cancer - The New England Journal of Medicine

A Phase 3 Trial of Bevacizumab in Ovarian Cancer The New England Journal of Medicine

Wholesale Gas Price Survey 2025 Edition - International Gas Union

Wholesale Gas Price Survey 2025 Edition International Gas Union

Increased Security Threats for vessels operating in the Gulf of Guinea - channel16.dryadglobal.com

Increased Security Threats for vessels operating in the Gulf of Guinea channel16.dryadglobal.com

How you can help with COVID-19 modelling - Nature

How you can help with COVID-19 modelling Nature

Updated: Youngkin supports National Guardsmen assisting with ICE deportations - VPM

Updated: Youngkin supports National Guardsmen assisting with ICE deportations VPM

Gregor Gog – anarchist, first street paper editor, and King of the Vagabonds - Street Roots

Gregor Gog – anarchist, first street paper editor, and King of the Vagabonds Street Roots

The impact of lymph node density on survival of cervical cancer patients - Nature

The impact of lymph node density on survival of cervical cancer patients Nature

Teachers’ Emotional Exhaustion: Associations With Their Typical Use of and Implicit Attitudes Toward Emotion Regulation Strategies - Frontiers

Teachers’ Emotional Exhaustion: Associations With Their Typical Use of and Implicit Attitudes Toward Emotion Regulation Strategies Frontiers

Atlantic piracy, current threats, and maritime governance in the Gulf of Guinea - Atlantic Council

Atlantic piracy, current threats, and maritime governance in the Gulf of Guinea Atlantic Council

2025 Wholesale Gas Price Survey - International Gas Union

2025 Wholesale Gas Price Survey International Gas Union

Is Israel on the Verge of the Gog-Magog War? - AskDrBrown

Is Israel on the Verge of the Gog-Magog War? AskDrBrown

6 lessons from Singapore on upskilling work for the future - The World Economic Forum

6 lessons from Singapore on upskilling work for the future The World Economic Forum

Mary Jo Katchmark Obituary - Grosse Pointe Woods, MI - Dignity Memorial

Mary Jo Katchmark Obituary - Grosse Pointe Woods, MI Dignity Memorial

Maureen Guthman, BET Executive, Dies at 60 - Huntington Now

Maureen Guthman, BET Executive, Dies at 60 Huntington Now

Heightened Risk Area assessed in Gulf of Guinea - Safety4Sea

Heightened Risk Area assessed in Gulf of Guinea Safety4Sea

Elaine Albert Obituary (2006) - Hartford, CT - Hartford Courant - Legacy obituary

Elaine Albert Obituary (2006) - Hartford, CT - Hartford Courant Legacy obituary

Are Russia and Ukraine in Bible Prophecy? - Harvest.org

Are Russia and Ukraine in Bible Prophecy? Harvest.org

Nigeria - use of foreign security guards - gard.no

Nigeria - use of foreign security guards gard.no

The Girls' U16 Amateur - The RA

The Girls' U16 Amateur The R&A

Sharon Day Obituary (2017) - Phoenix, AZ - The Arizona Republic - Legacy obituary

Sharon Day Obituary (2017) - Phoenix, AZ - The Arizona Republic Legacy obituary

Mary Jo Katchmark - Grosse Pointe News

Mary Jo Katchmark Grosse Pointe News

How to get GOG Galaxy working on Linux - AddictiveTips

How to get GOG Galaxy working on Linux AddictiveTips

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer - The New England Journal of Medicine

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer The New England Journal of Medicine

Masiku Gog yaMagog ota ka hanagulwa po (Hesekiel 38) - JW.ORG

Masiku Gog yaMagog ota ka hanagulwa po (Hesekiel 38) JW.ORG

Former Grand Mufti Of Egypt Sheikh Dr. Ali Gomaa: The Destruction Of Israel Will Lead To A Battle In Which The Muslims Will Defeat America And Russia - MEMRI

Former Grand Mufti Of Egypt Sheikh Dr. Ali Gomaa: The Destruction Of Israel Will Lead To A Battle In Which The Muslims Will Defeat America And Russia MEMRI

Top The Gog Foundation, Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant